1. Kishi N, Matsuo Y, Menju T, Hamaji M, Nakakura A, Hanazawa H, Takehana K, Date H, Mizowaki T. Propensity score-based analysis of stereotactic body radiotherapy, lobectomy, and sublobar resection for stage I non-small cell lung cancer. J Radiat Res. 2023. 1. 142-153. doi:10.1093/jrr/rrac041
2. Masui T, Nagai K, Anazawa T, Sato A, Uchida Y, Nakano K, Yogo A, Kaneda A, Nakamura N, Yoshimura M, Mizowaki T, Uza N, Fukuda A, Matsumoto S, Kanai M, Isoda H, Mizumoto M, Seo S, Hata K, Taura K, Kawaguchi Y, Takaori K, Uemoto S, Hatano E. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution. BMC Cancer.22:119 2022
3. Machitori Y, Ito K, Kito S, Nakajima Y, Saito M, Karasawa K. Local control of stereotactic body radiotherapy with dynamic tumor tracking for lung tumors: a propensity score-matched analysis. Jpn J Clin Oncol. 2022;52(6):609-615. doi:10.1093/jjco/hyac003
4. Takehana K, Sakamoto R, Fujimoto K, Matsuo Y, Nakajima N, Yoshizawa A, Menju T, Nakamura M, Yamada R, Mizowaki T, Nakamoto Y. Peritumoral radiomics features on preoperative thin-slice CT images can predict the spread through air spaces of lung adenocarcinoma. Sci Rep. 2022;12:10323. doi:10.1038/s41598-022-14400-w
5. Sugimoto T, Fujimoto D, Sato Y, Tamiya M, Yokoi T, Taniguchi A, Hino A, Hata A, Uchida J, Fukuda Y, Hara S, Kanazu M, Matsumoto H, Kokubo M, Yamamoto N. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and Grade 1 radiation pneumonitis. Lung Cancer, 2022.
6. Iizuka Y, Hiraoka M, Kokubo M, Sakamoto T, Karasawa K, Murofushi K, Nakamura M, Matsuo Y, Morita S, Inokuchi H, Mizowaki T. Dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring of liver tumors using a gimbal-mounted linac: A multi-institutional phase II study. Clinical and Translational Radiation Oncology. 2023, 39, 100591, doi: 10.1016/j.ctro.2023.100591.